Standard testosterone replacement therapy, using injections, gels, or modern oral formulations, poses minimal risk to liver health for most men. The older oral androgens that were chemically modified to survive digestion (like methyltestosterone) carried real hepatotoxicity risks, but those formulations are largely obsolete. Current TRT options show no clinically significant liver damage in clinical trials, and in some cases, testosterone therapy actually improves liver function markers.
How Testosterone Interacts With the Liver
The liver has androgen receptors that respond directly to testosterone. When testosterone binds to these receptors, it increases insulin receptor activity and glycogen synthesis while decreasing fat production in liver cells. It also promotes cholesterol storage and fatty acid breakdown. These effects are specific to male biology: animal studies show that removing androgen receptors from the liver leads to fat accumulation and insulin resistance in males but not females.
This means testosterone isn’t just passing through the liver for processing. It plays an active role in how the liver handles fat and sugar. When testosterone levels are low, the liver loses some of its ability to regulate these processes efficiently, which can contribute to fatty liver disease over time.
TRT and Fatty Liver Disease
One of the more striking findings in recent research is that TRT may actually help reverse fatty liver disease in men with low testosterone. A systematic review and meta-analysis found that every study examined showed reduced liver fat in men receiving testosterone compared to those who didn’t. The LiFT randomized controlled trial went further, demonstrating that testosterone therapy could resolve fatty liver disease entirely in some patients and even reverse liver scarring (fibrosis).
Liver enzyme levels, the standard blood markers used to gauge liver stress, also improved. Men on testosterone showed better ALT, AST, GGT, and ALP levels compared to placebo groups. For men dealing with both low testosterone and metabolic syndrome, this is significant. Low testosterone and fatty liver disease frequently overlap, and treating the hormone deficiency appears to address the liver problem at its metabolic root rather than making it worse.
Why Older Oral Steroids Were Different
The reputation testosterone has for liver damage comes largely from a specific chemical modification called 17-alpha-alkylation. Older oral androgens like methyltestosterone were altered this way so they wouldn’t be broken down during digestion. The trade-off was that the modified molecule became directly toxic to liver cells.
These older compounds could cause four distinct types of liver injury: temporary spikes in liver enzymes, a condition called cholestasis where bile flow gets blocked (causing jaundice, dark urine, itching, and pale stools), a vascular condition called peliosis hepatis where blood-filled cavities form in the liver, and liver tumors. Tumors typically appeared after 5 to 15 years of use, though cases have been reported as early as 2 years in. In one study of 254 patients on long-term androgen therapy, 17% developed jaundice and another 18% had abnormal liver tests without jaundice.
These risks are tied to the chemical structure of those specific compounds, not to testosterone itself. Injectable testosterone, topical gels, and patches bypass the digestive tract entirely or use unmodified testosterone, avoiding this problem altogether.
Modern Oral Formulations
The FDA has approved newer oral testosterone products (sold as Jatenzo, Tlando, and Kyzatrex) that use testosterone undecanoate, an ester that gets absorbed through the lymphatic system rather than going straight to the liver through the portal vein. This design sidesteps the liver toxicity issue that plagued earlier oral options.
Clinical trial data for these drugs is reassuring on the liver front. In pooled phase 3 studies of Kyzatrex, there were no clinically significant changes in mean liver function test values, and no trends toward worsening over time. Only 0.9% of participants in one trial had a liver enzyme increase flagged as an adverse event. Four subjects across the pooled studies had liver-related events, but investigators deemed all of them unrelated to the drug. No clinically significant hepatotoxicity has been reported with any of the three approved oral formulations.
The primary safety concerns with these newer oral options are blood pressure elevation, increased red blood cell production (polycythemia), and changes in cholesterol levels. Liver damage isn’t among them.
Liver Monitoring During TRT
Despite the favorable safety profile, liver function tests remain part of routine TRT monitoring. The typical schedule calls for blood work every 3 to 6 months during the first year of therapy, every 6 to 12 months in the second year, and annually after that once levels are stable. Any time the dose, frequency, or formulation changes, repeat testing is recommended within about 8 weeks for gels or at the next scheduled injection cycle.
If liver enzymes come back mildly elevated (less than three times the upper limit of normal), the standard approach is to review medications and alcohol intake, then retest in 4 to 6 weeks. Persistent abnormalities prompt further investigation, including screening for hepatitis, autoimmune conditions, and liver imaging. If enzymes rise above three times the upper limit of normal, testosterone therapy is typically paused until the cause is identified.
Warning Signs of Liver Stress
Liver problems rarely appear suddenly, but there are symptoms worth knowing. Yellowing of the skin or eyes (jaundice), unusually dark urine, pale or clay-colored stools, persistent itching, loss of appetite, abdominal cramping, and unexplained nausea or vomiting are all signs that bile flow may be disrupted. These symptoms were characteristic of the cholestatic jaundice caused by older oral androgens and would be unusual with modern TRT, but they warrant prompt medical attention regardless of the cause.
Most men on properly dosed, physician-monitored TRT using current formulations will never experience liver complications. The liver enzymes checked during routine blood work serve as an early detection system, catching subtle changes long before symptoms would appear.